Michael R. Lewis

Dr. Michael R. Lewis


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
MLMichael R. Lewis
Michael R. Lewis
JZJiuli Zhang
Jiuli Zhang
FJFang Jia
Fang Jia
NONellie K. Owen
Nellie K. Owen
CCCathy S. Cutler
Cathy S. Cutler
DADonald B. Axworthy
Donald B. Axworthy

1 November 2002 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
MLMichael R. Lewis
Michael R. Lewis
FJFang Jia
Fang Jia
FGFabio Gallazzi
Fabio Gallazzi
YWYi Wang
Yi Wang
JZJiuli Zhang
Jiuli Zhang
MHMark Hannink
Mark Hannink

1 August 2003
Verified
Journal Article
Closed access
MLMichael R. Lewis
Michael R. Lewis
MWMu Wang
Mu Wang
DADonald B Axworthy
Donald B Axworthy
LTLouis J Theodore
Louis J Theodore
RMRobert W Mallet
Robert W Mallet
CACarolyn J. Anderson
Carolyn J. Anderson

14 November 2011 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
HMHuma Mohsin
Huma Mohsin
FJFang Jia
Fang Jia
JBJeffrey N. Bryan
Jeffrey N. Bryan
GSGeethapriya Sivaguru
Geethapriya Sivaguru
CCCathy S. Cutler
Cathy S. Cutler
MLMichael R. Lewis
Michael R. Lewis

20 February 2008 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
FJFang Jia
Fang Jia
SFSaid Daibes Figueroa
Said Daibes Figueroa
FGFabio Gallazzi
Fabio Gallazzi
BBBaghavathy S. Balaji
Baghavathy S. Balaji
MHMark Hannink
Mark Hannink
MLMichael R. Lewis
Michael R. Lewis
The bcl-2 gene is overexpressed in non-Hodgkin's lymphoma (NHL), such as small lymphocytic lymphoma (SLL), and many other cancers. Noninvasive imaging of bcl-2 expression has the potential to identify patients at risk for relapse or treatment failure. The purpose of this study was to synthesize and evaluate radiolabeled peptide nucleic acid (PNA)-peptide conjugates targeting bcl-2 gene expression. An 111In-labeled PNA complementary to the translational start site of bcl-2 messenger RNA was attached to Tyr3-octreotate for somatostatin receptor-mediated intracellular delivery. Methods: DOTA-anti-bcl-2-PNA-Tyr3-octreotate (1) and 3 control conjugates (DOTA-nonsense-PNA-Tyr3-octreotate (2), DOTA-anti-bcl-2-PNA-Ala[3,4,5,6]-substituted congener (3), and DOTA-Tyr3-octreotate (4) [DOTA is 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid]) were synthesized by standard solid-phase 9-fluorenylmethoxycarbonyl (Fmoc) chemistry. In vitro studies were performed in Mec-1 SLL cells, which express both bcl-2 messenger RNA and somatostatin receptors. Biodistributions and microSPECT/CT studies were performed in Mec-1–bearing SCID (severe combined immunodeficiency) mice, a new animal model of human SLL. Results: 111In-Labeled conjugate 1 was taken up by Mec-1 cells through a somatostatin receptor-mediated mechanism. Biodistribution studies showed specific tumor uptake of conjugate 1, the somatostatin analog 4, and the PNA nonsense conjugate 2, but not of the mutant peptide conjugate 3. Mec-1 tumors could be detected by microSPECT/CT using 111In-labeled DOTA-Tyr3-octreotate (4) and the targeted anti-bcl-2 conjugate (1), but not using the 2 negative control conjugates 2 and 3. Conclusion: A new 111In-labeled antisense PNA–peptide conjugate demonstrated proof of principle for molecular imaging of bcl-2 expression in a new mouse model of human SLL. This imaging agent may be useful for identifying NHL patients at risk for relapse and conventional treatment failure.

15 June 2011 in Cancer Biology & Therapy
Verified
Journal Article
Open access
JBJeffrey N. Bryan
Jeffrey N. Bryan
FJFang Jia
Fang Jia
HMHuma Mohsin
Huma Mohsin
GSGeethapriya Sivaguru
Geethapriya Sivaguru
CACarolyn J. Anderson
Carolyn J. Anderson
MLMichael R. Lewis
Michael R. Lewis
Background: We previously described a two-antibody model of 64Cu radioimmunotherapy to evaluate low-dose, solid-tumor response. This model was designed to test the hypothesis that cellular internal...